Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/28/2025

Sedation Properties of Antipsychotics

Sedative Effects

  • Ziprasidone is effective for rapid reduction of acute agitation in emergency settings with onset of action within 15-30 minutes after intramuscular administration, according to the American College of Emergency Physicians 1, 2
  • The American College of Emergency Physicians recommends ziprasidone for managing acute agitation related to various causes, including psychiatric disorders, alcohol intoxication, and substance-induced states 1, 2
  • Ziprasidone's sedative properties make it suitable for patients with psychotic disorders, with a significant reduction in agitation scores within 15-30 minutes of administration, as reported by the American Psychiatric Association 1, 2

Clinical Evidence

  • In emergency settings, ziprasidone 20 mg IM decreases agitation scores quickly and significantly decreases mean restraint time compared to historic controls, with a moderate strength of evidence, according to the American College of Emergency Physicians 3, 4
  • Studies show that ziprasidone IM was significantly more effective in reducing symptoms of acute psychosis than haloperidol IM when dosed every 4-6 hours as needed, with a high strength of evidence, as reported by the National Institute of Mental Health 3
  • The American College of Emergency Physicians notes that ziprasidone's sedative effects are evident by significant reduction in agitation rating scales within 15-30 minutes of administration, with a moderate strength of evidence 1, 2

Comparison with Cariprazine

  • Unlike ziprasidone, cariprazine is not indicated for acute agitation management and lacks the sedative profile that makes ziprasidone useful in emergency settings, according to the American Psychiatric Association 1, 2
  • Cariprazine is considered more activating and less sedating than ziprasidone, making it potentially more suitable for patients with negative symptoms or psychomotor retardation, with a low strength of evidence, as reported by the National Institute of Mental Health 1
  • The American Psychiatric Association notes that cariprazine's pharmacological profile as a partial agonist at dopamine D₂/D₃ receptors contributes to its more activating and less sedating properties compared to ziprasidone, with a moderate strength of evidence 1

Clinical Decision Making

  • The American College of Emergency Physicians recommends choosing ziprasidone when rapid sedation is required for acute agitation, with a high strength of evidence 2, 3, 1
  • The American Psychiatric Association suggests choosing cariprazine when sedation would be problematic, such as in patients with excessive daytime sleepiness, with a low strength of evidence 1, 4
  • The National Institute of Mental Health notes that ziprasidone is associated with QTc interval prolongation and should be used with caution in patients with cardiac risk factors, with a moderate strength of evidence 3

REFERENCES